MEDIA RELEASE

MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the development of digital health technologies (DHTs) tailored to the needs of individuals with frontotemporal degeneration (FTD). Redenlab, in partnership with a global consortium of academic, clinical, and industry leaders, played a key role in shaping this important work arising from the Holloway Summit in Miami, FL.

Frontotemporal degeneration is a rare, complex neurodegenerative disorder that leads to progressive decline in behaviour, speech, and movement. Despite its devastating impact, no approved therapies currently exist to slow or stop its progression. In this context, DHTs offer unprecedented potential to detect and monitor subtle changes in FTD’s clinical features, especially in the domains of speech and language – core markers Redenlab is uniquely positioned to capture.

The paper highlights an ecosystem of tools and apps being developed to track functional decline across cognitive, behavioural, and motor domains. It also addresses major challenges in DHT development, such as regulatory alignment, clinical meaningfulness, and patient-centric design. A roadmap is proposed to guide the creation of robust, fit-for-purpose DHTs that will accelerate therapeutic development and improve outcomes for people living with FTD.

Redenlab contributed its deep expertise in speech analytics and digital clinical markers, and partnered with over 20 leading organisations, including the University of Pennsylvania, AbbVie, McGill University, UCSF, The Association for Frontotemporal Degeneration, and the University of Melbourne.

“Our mission has always been to deliver clinically relevant speech based measures that make a difference in drug development and clinical care,” said Redenlab CEO Prof Adam Vogel. “This collaborative effort brings us closer to scalable, validated solutions that meet the needs of people with FTD.”

Featured digital tools & apps:
The study references several innovative applications designed to monitor FTD symptoms, many of which integrate real time data collection from voice, movement, and behavioural patterns – an area where Redenlab’s software tools are actively contributing.

The full paper, Developing digital health technologies for frontotemporal degeneration, is available via Alzheimer’s & Dementia.

For more information, visit www.redenlab.com

For media inquiries, please contact:
Gloria Macan
Chief Marketing Officer
Redenlab
Gmacan@redenlab.com

About Redenlab:
Redenlab is a leading techbio company specialising in speech analysis and linguistic assessment tools. With a mission to enhance decision-making in clinical trials and healthcare research, Redenlab leverages leading knowledge in communication and technology to measure and analyse speech patterns, providing valuable insights into neurological conditions. Their innovative solutions are paving the way for improved
monitoring and diagnostics, personalised treatment plans, and transformative advancements in neuroscience research.